Summary
A phase II trial of detorubicin (DTR) has been conducted on 164 patients with solid tumors. Regressions ≧50% were obtained in 23% of the breast carcinoma patients, in 17% of the head and neck carcinoma patients and melanoma patients, and in 6% of the uteri cervix carcinoma patients. DTR seems to be as toxic as adriamycin for bone marrow and heart, but might induce a little less alopecia.
Chairman: E. Pommatau; Councillor: G. Mathe; Secretary: M. Hayat; Members: S. Schraub, A. Monnier (Besancon); J. Chauvergne, J. Reboul, L. Traissac, M. Caudry (Bordeaux); J. Guerrin (Dijon); P. Cappelaere (Lille); E. Pommatau, F. Cheix, N. Bonnafous (Lyon); J. Gary-Bobo (Montpellier); O. Godin (Nantes); M. Schneider (Nice); A. Cattan, Ch. Pourny (Reims); H. Piquet, C. Jeanne, P. Bastit (Rouen); P. Serpantie (Saint-Etienne); J. M. Lang, R. Keiling, T. Klein (Strasbourg); B. Clavel, J. Berlie (Saint-Cloud); G. Mathe, M. Hayat, F. de Vassal (Hopital Paul-Brousse and ICIG, Villejuif); G. Brule, F. May-Levin (IGR, Lagrange); C. Cauchie, R. Maurus (Bruxelles); T. J. Kuipers (Rotterdam); C. Oliveira (Coimbra)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bernard J, Jacquillat C, Weil M, Boiron M, Tanzer J (1970) Present results in daunorubicin (rubidomycin, daunomycin). In: Mathe G (ed) Advances in the treatment of acute (blastic) leukemias. Springer, Heidelberg New York, pp 3–8
Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E III (1979) Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32) an adriamycin analog. Cancer Treat Rep 63:919–923
Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Casazza AM (1979) Preliminary phase I study of 4’-epi-adriamycin. Cancer Treat Rep 63:915–918
Carter SK, Di Marco A, Ghione M, Krakoff IH, Mathe G (eds) (1972) Adriamycin. Springer, Heidelberg New York
Clarysse A, Kenis Y, Mathe G (1976) Cancer chemotherapy. Its role in the treatment strategy of hematologic malignancies and solid tumors. Springer, Heidelberg New York
Dantchev D, Slioussartchouk V, Paintrand M, Hayat M, Bourut C, Mathe G (1979) Electron microscopy of the heart and light microscopy of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD 32 and aclacinomycin. Cancer Treat Rep 63:875–888
EORTC Leukemia and Hematosarcoma Cooperative Group (1970) Rubidomycin (or daunomycin): A clinical evaluation. In: Mathe G (ed) Advances in the treatment of acute (blastic) leukemias. Springer, Heidelberg New York, pp 9–13
EORTC Clinical Screening Group (1978) Detorubicin: Preliminary results of a phase II trial in solid tumors (abstr 37). Med Oncol 4:10
Hori S, Shirai M, Hirano S, Oki T (to be published) Antitumor activity of new anthracycline antibiotics, aclacinomycin A (NSC 208734) and its analogues, and their toxicity. Gann
Jacquillat CI, Auclerc MF, Weil M, Maral J, Degos L, Auclerc G, Tobelem G, Schaison G, Bernard J (1979) Clinical activity of detorubicin : a new anthracycline derivative. Cancer Treat Rep 63:889–893
Maral R, Ducep JB, Farge D, Ponsinet G, Reisdord D (1978) Preparation et activite antitumor ale, experimentale d’un nouvel antibiotique semi synthetique: la (dietoxyace-toxy) -14-daunorubicine (33921 RP). CR Acad Sci (Parais) [D] 286:443–446
Mathe G, Bayssas M, Gouveia J, Dantchev D, Ribaud P, Machover D, Misset JL, Schwarzenberg L, Jasmin C, Hayat M (1978) Preliminary results of a phase II trial of aclacinomycine in acute leukaemia and lymphosarcoma. An oncostatic anthracycline that is rarely cardiotoxic and induces no alopecia. Cancer Chemother Pharmacol 1:259–262
Ogawa M, Inagaki J, Horikoshi N, Inoue K, Chinen T, Ueoka H, Nagura E (1979) Clinical study of Aclacinomycin A. Cancer Treat Rep 63:931–934
Oki T, Matsuzawa Y, Yoshimoto A, Numata K, Kimatura I, Ori S, Takamatsu A, Umezawa H, Ishizuka M, Naganawa H, Suda H, Hamada M, Takeuchi T (1975) New antitumor antibiotics, aclacinomycins A and B. J Antiobiot (Tokyo) 28:830–834
Author information
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
EORTC Clinical Screening Group. (1980). Clinical Study of Detorubicin. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive